The Murky History of Merck’s Vioxx Merck’s decision to withdraw its popular arthritis drug Vioxx from the market in late […]

Contingency Plans Help Current Merck Crisis : In the wake of Merck & Co.’s announcement to pull Vioxx off the

Reviewing Drug Safety “The Food & Drug Administration has announced a major review of its system for monitoring the safety

The Stem Cell Gold Rush: Scientists around the country who study embryonic stem cells may be mourning four more years

Financial Snapshot For September 2004 In need of a boost.

Biotech: The “safe” drug bet? “Defensive pharma stocks have struggled while biotechs have flourished. Can this continue?”

Biotech: The “safe” drug bet? “Defensive pharma stocks have struggled while biotechs have flourished. Can this continue?”

Biotech execs have a sense of humor about elusive profits When Ernst & Young’s annual report on the biotechnology industry

Is That a Pilot in Your Pocket? “Somewhere in Florida, 25,000 disembodied rat neurons are thinking about flying an F-22.

Foresight or folly? Generics firms’ foray into NCEs A number of generics firms have, over the last few years, veered